Phase 2 N=236 Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching — 1.71; 1.34; 2.11; 2.06 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation
Functional Constipation
Primary: Colonic Transit at 24 Hours — 2.68; 3.12; 1.93 units on a scale — p=0.059
Phase 2 N=160 Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Change From Baseline in FVC (Percent of Predicted FVC Value [% Predicted]) to Week 48 — 74.51; 72.82; -2.71; -7.20 % predicted FVC — p== 0.0331
Phase 2 N=64 Study of T-PRED(TM) Compared to Pred Forte(R)
Cataract
Primary: Mean Aqueous Humor Prednisolone Acetate Concentration — 102.5; 127.5 ng/mL
Phase 2 N=56 A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
Waldenstrom's Macroglobulinemia · Multiple Myeloma
Primary: Percentage of Participants With Complete Response (CR), Partial Response (PR) and Minimal Response (MR) or Minor Response (MinR): (Response Rate) — 7.1; 38.1 percentage…
Phase 2 N=19 Neoadjuvant Ipilimumab in Prostate Cancer
Prostate Cancer
Primary: Immunologic Response: Number of Participants With Immune Response — 12; 7; 9 Participants
Phase 2 N=183 Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
Dry Eye Disease
Primary: Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test — 3.02; 2.15; 2.35; 1.35 mm
Phase 2 N=415 Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
Cataract · Inflammation
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells. — 35; 19; 15; 47 Participants
Phase 2 N=885 Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
Migraine · Acute Treatment of Migraine
Primary: Number of Pain Free Participants (Pain Freedom) at 2 Hours Post-dose — 14; 12; 27; 28 Participants
Phase 2 N=356 Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Mean Corneal Staining Score — 4.0; 3.9; 3.9; 4.4 score on a scale
Phase 2 N=26 Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemia
Primary: Very Good Partial Response Rate (VGPR) for IDR — 5 Participants
Phase 2 N=12 Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock
Severe Sepsis · Septic Shock
Primary: Evaluate the Safety Profile of Pioglitazone in Patients With Severe Sepsis and Septic Shock as the Number of Hypoglycemic Events — 0; 0 events — p=1.0
Phase 2 N=162 Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants
Chronic Hepatitis B
Primary: Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Level at Week 24 — -0.011; 0.033; -0.018; -0.035 log10 IU/mL — p=0.590
Phase 2 N=18 Walnuts to Achieve Lasting NUTrition to Prevent Diabetes
PreDiabetes · Overweight and Obesity
Primary: Number of Participants Recruited and Retained — 8; 9 Participants
Phase 2 N=90 Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
Opiate Dependence · Chronic Pain
Primary: Pain Intensity — 5.43; 5.92; 5.28; 4.75 units on a scale